Vision Capital Management Inc. Sells 116 Shares of Eli Lilly and Company (NYSE:LLY)

Vision Capital Management Inc. decreased its position in Eli Lilly and Company (NYSE:LLY) by 1.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,194 shares of the company’s stock after selling 116 shares during the period. Vision Capital Management Inc.’s holdings in Eli Lilly and Company were worth $5,608,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. FRG Family Wealth Advisors LLC lifted its stake in shares of Eli Lilly and Company by 1.8% in the second quarter. FRG Family Wealth Advisors LLC now owns 8,745 shares of the company’s stock worth $7,918,000 after buying an additional 155 shares in the last quarter. Andra AP fonden raised its holdings in Eli Lilly and Company by 52.9% in the 2nd quarter. Andra AP fonden now owns 63,300 shares of the company’s stock worth $57,311,000 after acquiring an additional 21,900 shares during the last quarter. Sachetta LLC lifted its position in Eli Lilly and Company by 34.5% in the 2nd quarter. Sachetta LLC now owns 230 shares of the company’s stock valued at $208,000 after acquiring an additional 59 shares in the last quarter. Bright Futures Wealth Management LLC. boosted its stake in Eli Lilly and Company by 7.8% during the 2nd quarter. Bright Futures Wealth Management LLC. now owns 1,136 shares of the company’s stock valued at $1,029,000 after purchasing an additional 82 shares during the last quarter. Finally, Global X Japan Co. Ltd. bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth $2,139,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $908.39 on Tuesday. The business has a 50-day simple moving average of $895.85 and a two-hundred day simple moving average of $829.55. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 52 week low of $516.57 and a 52 week high of $972.53. The stock has a market cap of $863.36 billion, a price-to-earnings ratio of 133.78, a PEG ratio of 2.73 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. On average, analysts expect that Eli Lilly and Company will post 16.51 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.57%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 1,441 shares of the company’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $915.02, for a total value of $1,318,543.82. Following the completion of the transaction, the insider now owns 97,367,369 shares of the company’s stock, valued at approximately $89,093,089,982.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 661,900 shares of company stock worth $604,721,602 in the last three months. Company insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Guggenheim upped their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Truist Financial restated a “buy” rating and set a $1,000.00 target price (up previously from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday. Deutsche Bank Aktiengesellschaft upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and increased their price objective for the company from $725.00 to $1,025.00 in a research report on Monday, August 12th. Finally, Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $961.76.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.